Jul 19, 2022
Matthew Robinson is the Senior Vice President of R&D at Immunome, which is leveraging the information in memory B cells to target antibody therapeutics to kill tumor cells.
Matthew explains, "At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor antigens, or the specific epitopes on infectious disease. Our platform allows us to see that disease through the lens of the human B cell. We can interrogate what those antibodies are binding to, and we can use that information to help other patients."
"Right now, we have a couple of programs ongoing that are either in the clinic or moving towards the clinic. We have a program in infectious disease and COVID that is currently in phase 1b trials. It's a three-antibody cocktail. Those were isolated from patients who made a very robust antibody response to the disease and fought it off very effectively. Each of those antibodies was selected because they have different mechanisms of action."
"Our lead oncology program is against an under-studied or an under-recognized anti-inflammatory cytokine. It's a molecule that the immune system makes to essentially tell the rest of its other components to stop making an immune response. We isolated an antibody from a head-and-neck cancer patient that pointed us towards IL-38 as being a potential important target for head and neck cancer."
@Immunome #COVID19 #ImmunoOncology #MemoryBCells #AntibodyTherapeutics #AntibodyDrugConjugates #AutoimmuneDiseases #InfectiousDiseases